TY - JOUR
T1 - Pemetrexed
T2 - A multitargeted antifolate agent with promising activity in solid tumors
AU - Adjei, A. A.
PY - 2000
Y1 - 2000
N2 - Pemetrexed disodium (ALIMTA(TM), LY231514 (MTA)) is a novel multitargeted antifolate, that inhibits at least three enzymes involved in folate metabolism and DNA synthesis. These enzymes are thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This agent has shown broad antitumor activity in phase II trials in a wide variety of solid tumors, including non-small cell lung cancer, breast, colon, pancreas, bladder, head and neck, and cervical carcinomas, and is undergoing randomized phase III studies. MTA has also shown promising activity in a broad range of tumors in combination with other active agents such as gemcitabine and cisplatin. The clinical pharmacology, toxicity and clinical activity of MTA are reviewed in this report.
AB - Pemetrexed disodium (ALIMTA(TM), LY231514 (MTA)) is a novel multitargeted antifolate, that inhibits at least three enzymes involved in folate metabolism and DNA synthesis. These enzymes are thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This agent has shown broad antitumor activity in phase II trials in a wide variety of solid tumors, including non-small cell lung cancer, breast, colon, pancreas, bladder, head and neck, and cervical carcinomas, and is undergoing randomized phase III studies. MTA has also shown promising activity in a broad range of tumors in combination with other active agents such as gemcitabine and cisplatin. The clinical pharmacology, toxicity and clinical activity of MTA are reviewed in this report.
KW - Multitargeted antifolate
KW - Solid tumors
KW - Thymidylate synthase
UR - http://www.scopus.com/inward/record.url?scp=0033758532&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033758532&partnerID=8YFLogxK
U2 - 10.1023/A:1008379101017
DO - 10.1023/A:1008379101017
M3 - Article
C2 - 11106124
AN - SCOPUS:0033758532
SN - 0923-7534
VL - 11
SP - 1335
EP - 1341
JO - Annals of Oncology
JF - Annals of Oncology
IS - 10
ER -